Immunovant (IMVT) Stock Price, News & Analysis

Company Overview

Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for autoimmune diseases. The company’s approach centers on targeting the neonatal Fc receptor (FcRn), a protein involved in the recycling of immunoglobulin G antibodies that can contribute to autoimmune activity.

Immunovant’s lead product candidate is batoclimab (IMVT-1401), a fully human monoclonal antibody designed to reduce circulating disease-causing antibodies. The company has evaluated batoclimab in several autoimmune conditions, including generalized myasthenia gravis and Graves’ disease, and has also pursued development in other antibody-mediated disorders. Its pipeline additionally includes IMVT-1402, a next-generation FcRn inhibitor intended for subcutaneous administration.

Immunovant was established as a subsidiary of Roivant Sciences and obtained rights to develop its FcRn antibody programs from HanAll Biopharma. The company conducts clinical development primarily through studies in the United States and other international markets. Pete Salzmann has served as Immunovant’s president and chief executive officer.

Key Stats

• Today's Range: $28.70 to $29.64
• 50-Day Range: $28.71 to $44.96
• 52-Week Range: $16.77 to $45.42
• Volume: 1.24 million shs
• Average Volume: 1.69 million shs
• Market Capitalization: $5.93 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $44.00
• Consensus Rating: Moderate Buy

Immunovant Stock Analysis - MarketRank™

Immunovant scored higher than 49% of companies evaluated by MarketBeat, and ranked 570th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Immunovant has received a consensus rating of Moderate Buy. The company's average rating score is 2.58, and is based on no strong buy ratings, 8 buy ratings, 3 hold ratings, and 1 sell rating.

Upside Potential

Immunovant has a consensus price target of $44.00, representing about 53.3% upside from its current price of $28.71.

Amount of Analyst Coverage

Immunovant has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Immunovant are expected to decrease in the coming year, from ($2.96) to ($3.01) per share.

Price to Book Value per Share Ratio

Immunovant has a P/B Ratio of 6.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.60% of the float of Immunovant has been sold short.

Short Interest Ratio / Days to Cover

Immunovant has a short interest ratio ("days to cover") of 9.64.

Change versus previous month

Short interest in Immunovant has recently increased by 0.94%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Immunovant does not currently pay a dividend.

Dividend Growth

Immunovant does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.45

News Sentiment

Immunovant has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 15 news articles for Immunovant this week, compared to 4 articles on an average week.

Search Interest

5 people have searched for IMVT on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Immunovant to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 1.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Immunovant insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $524,482.00 in company stock.

Percentage Held by Insiders

1.90% of the stock of Immunovant is held by insiders.

Percentage Held by Institutions

47.08% of the stock of Immunovant is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/13/2026
• Next Earnings (Estimated): 11/09/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:IMVT
• CIK: 1764013
• Web: www.immunovant.com
• Phone: (917) 410-3120
• Fax: N/A
• Employees: 315
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Immunovant: $44.00
• High Price Target: $62.00
• Low Price Target: $28.00
• Potential Upside/Downside: +53.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.58
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.82)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$505.61 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -69.59%
• Return on Assets: -62.49%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.27
• Quick Ratio: 7.27

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.19 per share
• Price / Book: 6.85

Miscellaneous

• Outstanding Shares: 206,550,000
• Free Float: 202,628,000
• Market Cap: $5.93 billion
• Optionable: Optionable
• Beta: 0.84